Nav: Home

Viral escape hatch could be treatment target for hepatitis E, Princeton-led study finds

January 16, 2017

PRINCETON, N.J. -- The technique that the hepatitis E virus -- an emerging liver virus historically found in developing countries but now on the rise in Europe -- uses to spread could present a weak spot scientists can exploit to treat the disease, according to a Princeton University-led study.

The findings appear in the journal Proceedings of the National Academy of Sciences. A PDF is available on request.

Researchers report that when the hepatitis E virus infects a cell, it makes proteins that poke holes in the cell's membrane to allow newly made virus particles to escape and spread. Known as viroporins, these proteins create channels that allow the inflow and outflow of charged particles called ions that disrupt the infected cell's physiology and lead it to release the infectious particles.

Yet the very proteins the virus uses to escape a host cell and spread infection could in fact provide an avenue for developing antivirals that target hepatitis E, the researchers said. They suggest that curtailing the virus' ability to produce viroporins may prevent the pathogen from being able to burst forth from infected cells to attack other cells. Drugs that target viroporin production have already been developed for other viruses that employ the proteins to aid infection, including hepatitis C virus, HIV-1 and influenza A.

"These proteins cause changes in the cell membrane that allow the newly made hepatitis E virus particles to spread," said senior author Alexander Ploss, a Princeton assistant professor of molecular biology. "If we can prevent the release of viral particles, we could slow the spread of infection and give the immune system time to clear the virus from the body."

Viruses multiply by taking over an infected cell's reproductive machinery so that they can make millions of viral copies. These copies then exit the infected cell, usually by bursting it open. Hepatitis E virus, the researchers found, is among a subset of viruses that prime the cell membrane for bursting by using viroporins. Exactly how the transmission of ions through viroporin channels causes the host cell to burst is an active area of research. It may be that ions entering through the pores draw in so much water that the cell explodes like a water balloon, Ploss said.

The available treatments for hepatitis E are not specific and have side effects. Believed to be uncommon in the United States, the virus has become prevalent in Europe in the last few decades where it is contracted primarily via the consumption of undercooked pork and foods such as raw pork-liver sausage. In developing nations, the disease is primarily spread through contaminated food and water. Globally, the virus causes about 20 million cases per year.

In most cases, the virus causes only mild, short-term symptoms such as fever and jaundice. For pregnant women and people with compromised immune systems, however, the disease can be much more severe. Among women in the third trimester of pregnancy, fatality rates as high as 25 percent have been reported, according to the World Health Organization. Immunocompromised individuals, including those infected with HIV and organ-transplant patients taking immunosuppressant drugs, can develop a persistent infection that can eventually destroy their liver.

The researchers discovered that within the virus's genomic material -- which in this virus is RNA -- a section known as open reading frame 3 (ORF3) contains the "instructions" the virus uses to make viroporins. Qiang Ding, a postdoctoral fellow in Princeton's Department of Molecular Biology, performed a series of experiments aimed at finding the function of the protein made from ORF3. Ding's colleagues at Princeton included research specialist Brigitte Heller, graduate students Bokai Song and Ila Nimgaonkar, and research specialist Gabriela Hrebikova, all in molecular biology.

During these experiments, Ding and his colleagues noted several pieces of evidence indicating that the ORF3 protein could span the cell's membrane. They noticed that the protein collected on one of the cell's internal membranes surrounding an organelle known as the endoplasmic reticulum. The researchers also noticed that the proteins formed small clusters that resembled ion channels.

To find out whether these membrane-spanning proteins were needed for letting virus particles escape the cell, Ding and his colleagues removed the ORF3 RNA from the hepatitis E virus. They found that without ORF3, the virus could not exit the infected cell. When they substituted in RNA from influenza A virus -- which also use viroporins -- the researchers were able to restore the ability of the virus particles to exit the host cell.

A more direct test came with help from researchers at nearby Rutgers University. When ions exit or enter the cell, they cause measurable changes in the electrical currents traveling through the membrane. These currents can be measured with a technique called patch clamping, which involves measuring the currents inside and outside the cell.

To conduct these tests, Ploss contacted Jorge Contreras, an assistant professor at Rutgers New Jersey Medical School. Contreras and graduate student Juan Capuccino taught Ding how to do the experiments, which involved adding ORF3 RNA to cells isolated from Xenopus laevis, or the African clawed frog.

The researchers found that the frog cells expressing ORF3 RNA allowed ion fluxes across the cell membrane whereas X. laevis cells without the viral RNA did not. "We recorded the currents and if the protein was able to facilitate the movement of ions across the membrane down their concentration gradient, it was working as an ion channel," Contreras said.

The researchers are now exploring the structure of ORF3 to look for areas that could become treatment targets, Ploss said. "We are working on identifying parts of the protein that could possibly prevent the formation of the ion channel or prevent the flux of ions through the channel," Ploss said.
-end-
Assistant Professor Alexander Ploss is available to comment at aploss@princeton.edu.

The research was supported by the Burroughs Wellcome Fund and the New Jersey Commission on Cancer Research.

Broadcast studios: Princeton has TV and radio studios available for interviews. For more information, visit: https://www.princeton.edu/bc/services/ or contact bctv@princeton.edu, (609) 258-7872.

Princeton University

Related Hepatitis Articles:

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum M√ľnchen and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
Countries risk 'running out' of hepatitis C patients to treat, says World Hepatitis Alliance
The latest data on the global hepatitis C epidemic, released today at the World Hepatitis Summit in Sao Paulo, Brazil, reveal that most countries (especially high-income countries) are running out of patients to treat because of the low diagnosis rates worldwide.
Australia currently on track to eliminate hepatitis C by 2030, but challenges remain for hepatitis B
New data released at this year's World Hepatitis Summit in Sao Paulo, Brazil, shows that Australia is currently on track to eliminate hepatitis C thanks to its huge efforts to enable population-wide access to treatment.
More Hepatitis News and Hepatitis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.